Douglas has over 20 years of clinical research experience; has been working globally in project management since 2003, with more than 15 years spent in leadership roles. He has extensive experience working in peri- and post-approval research and has overseen many different types of studies, including observational, PASS and PAES, health outcomes studies, marketing studies, Expanded Access/Compassionate Use Programs, and Phase IIIb / Phase IV studies. Douglas leads the European project management team and is responsible for delivering global non-interventional studies. He is an expert in the operations and nuances of these types of studies as they require a different operational model as compared to Phase III studies.
Previously, Douglas worked as a Project Director for i3 Research, overseeing phase I-IV oncology studies. Prior to that he worked for six years at Quintiles as a project manager/project director, specializing in peri- and post-approval research, during which he worked at the offices of Elan Pharmaceuticals and GlaxoSmithKline developing compounds to treat Inflammatory Bowel Disease and Medical Genetics drug discovery respectively. He also worked for Serono Pharmaceuticals as a Clinical research manager/medical manager for four years conducting medical marketing research in Growth Hormone Deficiency and Multiple Sclerosis, and at Schering Plough for six years where he began his career in clinical research investigating the impact of novel cytokine products in different diseases (such as Cancer and Rheumatoid Arthritis). Douglas also worked on some of the first gene therapy trials helping to further understand the impact of this drug development approach in oncology.
Douglas has a BSc in Applied Biological Sciences from the University of Bristol.